ResMed (NYSE:RMD) Price Target Raised to $270.00

ResMed (NYSE:RMD) had its price target increased by equities research analysts at Citigroup from $240.00 to $270.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical equipment provider’s stock. Citigroup‘s price target would indicate a potential upside of 17.00% from the company’s current price.

Several other research analysts have also weighed in on RMD. Rothschild & Co Redburn started coverage on shares of ResMed in a report on Wednesday, August 19th. They set a “neutral” rating and a $230.00 price objective on the stock. Royal Bank Of Canada boosted their target price on shares of ResMed from $262.00 to $288.00 and gave the company an “outperform” rating in a research note on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a report on Friday. Jefferies Financial Group lowered their price target on shares of ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a research report on Friday, July 10th. Finally, Wells Fargo & Company lifted their price objective on shares of ResMed from $215.00 to $250.00 and gave the company an “equal weight” rating in a research note on Friday. Seven equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, ResMed currently has a consensus rating of “Hold” and a consensus price target of $253.69.

ResMed Stock Performance

Shares of RMD stock traded down $22.07 during mid-day trading on Friday, hitting $230.76. The stock had a trading volume of 3,441,073 shares, compared to its average volume of 1,302,642. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.10 and a quick ratio of 2.42. The firm has a market cap of $32.45 billion, a PE ratio of 22.12, a PEG ratio of 1.53 and a beta of 0.75. ResMed has a fifty-two week low of $180.26 and a fifty-two week high of $277.67. The company’s 50-day simple moving average is $231.83 and its 200-day simple moving average is $225.57.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.67 by $0.24. The business had revenue of $1.41 billion for the quarter, compared to analysts’ expectations of $1.39 billion. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.55 EPS. Sell-side analysts anticipate that ResMed will post 12.11 earnings per share for the current year.

Insider Buying and Selling

In other news, General Counsel Michael J. Rider sold 400 shares of the business’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $255.00, for a total value of $102,000.00. Following the transaction, the general counsel directly owned 12,318 shares of the company’s stock, valued at $3,141,090. The trade was a 3.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,800,000.00. Following the transaction, the director owned 52,773 shares in the company, valued at approximately $11,873,925. The trade was a 13.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 24,343 shares of company stock valued at $5,396,098. 0.58% of the stock is owned by company insiders.

Institutional Investors Weigh In On ResMed

Several institutional investors have recently bought and sold shares of RMD. Bell Investment Advisors Inc acquired a new position in shares of ResMed during the 2nd quarter worth approximately $26,000. Trust Co. of Vermont bought a new position in shares of ResMed in the second quarter worth $39,000. Kelleher Financial Advisors acquired a new stake in ResMed during the second quarter worth about $47,000. Provenance Wealth Advisors LLC acquired a new position in shares of ResMed during the 3rd quarter worth $55,000. Finally, Ballast Advisors LLC acquired a new position in ResMed during the 1st quarter worth approximately $84,000. Institutional investors own 54.98% of the company’s stock.

ResMed News Roundup

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Quarterly results exceeded expectations. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share, above the $2.67 consensus estimate, while revenue rose 5.9% year over year to $1.41 billion, topping the $1.39 billion forecast. Growth was supported by sustained demand for sleep devices, productivity improvements and higher gross margins. ResMed Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Analysts raised their price targets. Royal Bank of Canada increased its target from $262 to $288 and maintained an “outperform” rating. KeyCorp also lifted its target from $267 to $277 and retained an “overweight” rating, signaling continued confidence in ResMed’s long-term growth prospects.
• Positive Sentiment: Shareholder returns remain supported. ResMed declared a quarterly dividend of $0.66 per share, equivalent to $2.64 annually and a yield of approximately 1.1%. ResMed Posts Strong Q1 Results and Shareholder Returns
• Neutral Sentiment: Wells Fargo raised its target but kept an “equal weight” rating. The firm increased its price target from $215 to $250, suggesting valuation upside while stopping short of recommending the stock more aggressively. Wells Fargo Adjusts Price Target on ResMed
• Negative Sentiment: Full-year guidance was unchanged. Although ResMed beat quarterly estimates, management maintained its prior annual outlook. Investors may have been looking for an upgrade following the earnings beat, making the lack of increased guidance a likely reason for the stock’s decline.

ResMed Company Profile

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.